#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Prevalence of the Diabetic Retinopathy and Genetic Factors Significance in the Development of Diabetic Retinopathy in Patients with Diabetes Mellitus type I and II in Slovakia (DIARET SK study). Overview of Actual Findings and Design of the Epidemiological DIARET SK Study


Authors: V. Krásnik 1;  J. Štefaničková 1;  J. Fabková 2;  D. Bucková 2;  M. Helbich 3
Authors place of work: Klinika oftalmológie LF UK a UNB, Bratislava, prednosta doc. MUDr. Vladimír Krásnik, PhD. 1;  Novartis Slovakia s. r. o., Bratislava, riaditeľka Marianthi Psaha 2;  Caldera, s. r. o, Banská Štiavnica, Mgr. Miroslav Helbich, PhD. 3
Published in the journal: Čes. a slov. Oftal., 71, 2015, No. 5, p. 237-242
Category: Original Article

Summary

Introduction:
Diabetic retinopathy (DR) is the second most common microvascular complication and the most common cause of blindness in patients with diabetes mellitus (DM). Despite the ongoing research, the findings of diabetic retinopathy epidemiological and risk factors are, until now, not consistent. More finding may be revealed by epidemiological studies, consistently mapping DR epidemiology under the current possibilities of investigations and treatment of the DM.

DIARET SK:
DIARET SK Study, with 5 000 enrolled patients with diabetes mellitus in the Slovak Republic, is, until now, the largest epidemiological study to set the prevalence of diabetic retinopathy. The primary aim is to establish the prevalence of diabetic retinopathy in patients with diabetes mellitus type I and II, according to the duration of the disease. The secondary aim is to establish prevalence of the different stages of the DR and diabetic macular edema (DME) and analysis of the risk factors influence. Included are patients with DM type I and II regardless to the ocular complications history and the period of DM duration. Each enrolled patient has both complex diabetic and ophthalmic examinations.

Projects to establish DR prevalence:
Tens of projects concerned with diabetic retinopathy epidemiology with different approaches to establish the prevalence and with different patients population. Results from different studies vary significantly (from 12.3 % to 66.9 %). The results depend on the design of the study and the patients recruitment, used examination methods, specific patients population with regard to the geography, prevalence of risk factors, period of diabetes duration, glycated hemoglobin (HbA1C) level, blood pressure, and is higher in type I diabetic patients. The most accurate results are from population epidemiological studies with well-controlled patient recruitment and uniform complex examination that are similar to the DIARET SK study.

Conclusion:
The DIARET SK study represents the largest epidemiological study to establish the prevalence of the diabetic retinopathy in patients with DM type I and II. Thanks to the quality design, similar to the already published studies, but with larger number of patients and newest examinations methods, the DIARET SK study has the aspiration to obtain the most accurate up to date data of diabetic retinopathy prevalence and risk factors influence to its outbreak. The patients’ recruitment started in February 2015. The expected date of patients’ recruitment termination is in the end of the year 2015, and the data analysis in 2016.

Key words:
diabetic retinopathy, prevalence, epidemiological study, macular diabetic edema, diabetes mellitus


Zdroje

1. Cade WT.: Diabetes-Related Microvascular and Macrovascular Diseases in the Physical Therapy Setting. Phys Ther, 2008, 88(11): 1322–1335.

2. Wilkinson, Ch. P. et al.: Classification of Diabetic Retinopathy: A proposed International Clinical Disease Severity Grading Scale for Diabetic Retinopathy and Diabetic Macular Edema, 2002, http://www.medscape.com

3. Early Treatment Diabetic Retinopathy Study Report Number 1: Photocoagulation for diabetic macular edema. Arch Ophthalmol, 1985; 103:1796–1806.

4. International Diabetes Federation. IDF Diabetes Atlas, 6th edn. Brussels, Belgium: International Diabetes Federation, 2013. http://www.idf.org/diabetesatlas

5. Shaw J.E. et al.: Global estimates of the prevalence of diabetes for 2010 and 2030. Diab Res Clin Practice, 2010; 87: 4–14.

6. Činnosť diabetologických ambulancií v SR 2013, Národné centrum zdravotníckych informácií, Bratislava 2014.

7. Arar NH. et al.: Heritability of the severity of diabetic retinopathy: the FIND-Eye Study. Invest Ophthalmol Vis Sci, 2008; 49: 3839–45.

8. Kaidonis, G. et al.: Genetic study of diabetic retinopathy: recruitment methodology and analysis of baseline characteristics. Clinical and Experimental Ophthalmology, 2014; 42: 486–493.

9. Mangione CM. et al.: National Eye Institute Visual Function Questionnaire Field Test Investigator: development of the 25-item National Eye Institute function questionnair. Arch Ophthalmol, 2001; 119: 1050–1058.

10. Vodrážková E. et al.: Psychometrická validácia verzie „dotazníka zrakových funkcíí-25 v podmienkach Slovenska“. Čes a Slov Oftal. 2012; 68(3), 102–108.

11. Klein, R. et al.: The Wisconsin Epidemiologic Study of Diabetic Retinopathy, XXIII: The 25-Year Incidence of Visual Impairment in Type 1 Diabetes Mellitus. Ophthalmology, 2010; 117: 63–70.

12. Klein R, Klein BE, Moss SE et al.: The Wisconsin Epidemiologic Study of Diabetic Retinopathy, II. Prevalence and Risk of Diabetic Retinopathy when Age at Diagnosis Is Less Than 30 Years. Arch Ophthalmol, 1984; 102: 520–526.

13. Klein R, Moss SE, Klein BE, et al.: The Wisconsin Epidemiologic Study of Diabetic Retinopathy, III. Prevalence and Risk of Diabetic Retinopathy when Age at Diagnosis Is 30 or More Years. Arch Ophthalmol, 1984,102: 527–532.

14. Sloan FA. et al.: Change in incidence of diabetes mellitus/related eye disease among US elderly persons, 1994–2005. Arch Ophtalmol, 2008; 126: 1548–1553.

15. Yau JW, Rogers SL, Kawasaki R, et al.: Meta-Analysis for Eye Disease (META-EYE) Study Group. Global prevalence and major risk factors of diabetic retinopathy, Diabetes Care, 2012; 35: 556–64.

16. Kempen et al.: The Prevalence of Diabetic Retinopathy Among Adults in the United States. Arch Ophthalmol, 2004; 122(4): 552–563.

17. Ruta et al.: Prevalence of diabetic retinopathy in Type 2 diabetes in developing and developed countries. Diabet Med, 2013; 30: 387–98.

18. Olafsdottir E. et al.: The prevalence of retinopathy in subjects with and without type 2 diabetes mellitus. Acta Ophthalmol, 2014; 92: 133–137.

19. Rodriguez-Poncelas A. et al.: Prevalence of diabetic retinopathy in individuals with type 2 diabetes who had recorded diabetic retinopathy from retinal photographs in Catalonia (Spain). Br J Ophthalmol, 2015; 0:1–6.

20. Klein et al.: The association of atherosclerosis, vascular risk factors, and retinopathy in adults with diabetes: the atherosclerosis risk in communities study. Ophthalmology, 2002; Jul, 109(7): 1225–34.

21. The Diabetes Control and Complications Trial Reasearch Group. Clustering of long-term complications in families with diabetes in the diabetes control and complications trial. Diabetes, 1997; 46: 1829–1839.

22. Looker HC. et al.: Genome-wide linkage analyses to identify loci for diabetic retinopathy. Diabetes, 2007; 56: 1160–6.

23. Hallman DMD et al.: A genome-wide linkage scan for diabetic retinopathy susceptibility genes in Mexican Americans with type 2 diabetes from Starr County. Texas, Diabetes, 2007, 56: 1167–73.

24. Szabo S.M.et al.: Patient Preferences for Diabetic Retinopathy Health States. Invest Ophthalmol Vis Sci, 2010; 51, 3387–3394.

Štítky
Ophthalmology
Prihlásenie
Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa

#ADS_BOTTOM_SCRIPTS#